UBS AM’s Sutro Biopharma STRO Stock Holding History

UBS AM’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,010	Closed	-$165K	–	2767
2022 Q1	$165K	Buy	+2,010	New	+$191K	﹤0.01%	2704

Other funds holding STRO

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

UBS AM's STRO Position: Q2 2022 in Review

UBS AM sold out of Sutro Biopharma (STRO) in Q2 2022, closing a stake of 2,010 shares — an estimated $165K sold.

UBS AM first reported a position in STRO in Q1 2022 and held it in 1 quarter. The position peaked at $165K in Q1 2022. 114 funds tracked by Wall St. Rank hold STRO as of Q2 2022.

UBS AM reported no remaining Sutro Biopharma position as of Q2 2022 after selling out during the quarter.
UBS AM sold 2,010 Sutro Biopharma shares in Q2 2022, an estimated $165K.
UBS AM first reported a position in Sutro Biopharma in Q1 2022 and held it in 1 quarter.
UBS AM's Sutro Biopharma position peaked at $165K in Q1 2022.
114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.